Home › Sickle Cell Disease › NCT06016634

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

* Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
* Ability to provide written informed consent
* Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
* Negative urine pregnancy test for anyone of childbearing potential at study entry

Exclusion Criteria:

* Pregnant women
* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Prisoners
* Hospitalizations (for any cause) within 2 weeks of study entry

About the study

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

What is being tested

• Alendronate Sodium (drug)

Sponsor: University of California, Davis · Participants: 30 · Started: Mar 9, 2026

Contact the study team

• Leyla Y Teos, PhD · Phone: (916) 460-2749

Official record on ClinicalTrials.gov — NCT06016634

Locations in the U.S.

Conditions

• Sickle Cell Disease
• Osteonecrosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.